

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Blinatumomab for treating minimal residual B- precursor acute lymphoblastic leukaemia in remission [ID1036]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During the scoping workshop it was noted that blinatumomab is currently being used in children as well but the remit was for adults.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equality issues were identified in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No additional issues have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 20/02/2019

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
--

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Issue date: June 2019

No.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The technology is recommended within MA but optimised for people with acute lymphoblastic leukaemia with minimal residual disease of at least 0.1%, only if the disease is in first complete remission. This should not be more difficult for a specific group to access compared with other groups because MRD testing is routine for all patients.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

Approved by Associate Director (name): ... Frances Sutcliffe

Date: 23/05/2019